A clinical trial to study homoeopathic management of stress in essential hypertension patients in age group of 35-80 years.

Role of homoeopathic medicines in management of stress in essential hypertension patients in the age group of 35-80 years.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034396

Enrollment

Registered

2021-06-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Individualized Homoeopathic Medicine Comparator agent - Not applicable: Potentized, Individualized homoeopathic medicine Intervention2: Individualized homoeopathic medicine: Potentized

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of both sexes & age group between 35-80 yrs. 2. Patients presenting with pre-diagnosed mild to moderate essential hypertension without any major systemic complications whose exciting or maintaining cause of essential hypertension is identified to be stress. 3. Patients on allopathic treatment for essential hypertension fulfilling above two inclusion criterias will be enrolled. 4. Patients on no allopathic or no homoeopathic treatment (from other doctors for essential hypertension treatment) fulfilling the first two inclusion criterias will be enrolled. 5. The ability to give informed consent & comply with study procedures.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women with essential hypertension. 2. Patients with severe essential hypertension. 3. Patients with secondary hypertension. 4. Patients who require emergency medical interventions or Severe co-morbidities. 5. Patients on homoeopathic treatment for essential hypertension from another doctor will be excluded. 6. Simultaneous participation in other clinical studies or completion of participation in a study less than 6 months prior (patients are to be explicitly asked about this).

Design outcomes

Primary

Measure	Time frame
1. Improvement (i.e. Reduction in score after the study) in Perceived Stress Scale Score (PSS) used for stress assessment BEFORE and AFTER the study. 2. Improvement in SF36 (by RAND) used for Quality of life assessment of the essential hypertension patients BEFORE and AFTER the study.Timepoint: 1. Improvement (i.e. Reduction in score after the study) in Perceived Stress Scale Score (PSS) used for stress assessment at baseline and after 3 months. 2. Improvement in SF36 (by RAND) used for Quality of life assessment of the essential hypertension patients at baseline and after 3 months.	—

Measure

Time frame

1. Improvement (i.e. Reduction in score after the study) in Perceived Stress Scale Score (PSS) used for stress assessment BEFORE and AFTER the study. 2. Improvement in SF36 (by RAND) used for Quality of life assessment of the essential hypertension patients BEFORE and AFTER the study.Timepoint: 1. Improvement (i.e. Reduction in score after the study) in Perceived Stress Scale Score (PSS) used for stress assessment at baseline and after 3 months. 2. Improvement in SF36 (by RAND) used for Quality of life assessment of the essential hypertension patients at baseline and after 3 months.

—

Secondary

Measure	Time frame
Improvement in essential hypertension assessed by reduction in levels of blood pressure after 3 months of treatment.Timepoint: Changes in levels of blood pressure at baseline and after 3 months of treatment.	—

Countries

India

Contacts

Public ContactDr Mrinal Ashish Nerlekar

Bharati Vidyapeeth Deemed to be University, Pune.

mrinalnerlekar@gmail.com9422321397

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026